Trials / Terminated
TerminatedNCT03757351
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNL747 | Repeating oral dose |
| DRUG | Placebo | Repeating oral dose |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2020-06-18
- Completion
- 2020-06-18
- First posted
- 2018-11-28
- Last updated
- 2025-09-22
Locations
3 sites across 2 countries: United States, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03757351. Inclusion in this directory is not an endorsement.